A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma. A trial of the Princess Margaret Hospital, Chicago and California Cancer Phase II Consortia

Abstract Objective The aim of this multi-institutional non randomized phase II trial was to determine the efficacy and safety of single agent aflibercept (VEGF Trap), a recombinant fusion protein that blocks multiple vascular endothelial growth factor isoforms, in women with gynecologic soft tissue...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Gynecologic oncology 2012-04, Vol.125 (1), p.136-140
Hauptverfasser:	Mackay, H.J, Buckanovich, R.J, Hirte, H, Correa, R, Hoskins, P, Biagi, J, Martin, L.P, Fleming, G.F, Morgan, R, Wang, L, Polintan, R, Oza, A.M
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aflibercept (VEGF Trap) Aged Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use California Carcinosarcoma Carcinosarcoma - drug therapy Carcinosarcoma - mortality Chicago Disease-Free Survival Drug Administration Schedule Female Genital Neoplasms, Female - drug therapy Genital Neoplasms, Female - mortality Hematology, Oncology and Palliative Medicine Humans Kaplan-Meier Estimate Leiomyosarcoma - drug therapy Leiomyosarcoma - mortality Middle Aged Obstetrics and Gynecology Phase II Receptors, Vascular Endothelial Growth Factor Recombinant Fusion Proteins - adverse effects Recombinant Fusion Proteins - therapeutic use Treatment Outcome Uterine leiomyosarcoma
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!